Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 3/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120398 | 0.88 | TTK (0.52) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL120513 | 0.86 | KMT2A (0.46) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL121930 | 0.85 | KMT2A (0.47) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL120443 | 0.84 | KDM4E (0.46) | KMT2APOLBACP1BRD4ADORA3 | |
| SCHEMBL3811367 | 0.84 | TTK (0.48) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL120630 | 0.83 | TTK (0.43) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL3722009 | 0.83 | KMT2A (0.46) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL3720480 | 0.82 | TTK (0.43) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL122273 | 0.82 | TTK (0.47) | KMT2APOLBTTKACP1BRD4 | |
| SCHEMBL121023 | 0.82 | TTK (0.45) | KMT2APOLBTTKACP1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | claimed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | claimed |
| EP-2424537-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | Bayer Pharma Aktiengesellschaft (DE) | 2012-03-07 | — | — | EP | claimed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | claimed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | TTBK1, TTK, TTBK2 | KMT2A 4171/4885POLB 1173/4885TTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.